$ACHN Headlines In focus: New highs premature? 9:03

New Post Public Reply Private Reply Replies (0) Message Board

Jun 22, 2014 at 11:49 AM

$ACHN Headlines

In focus: New highs premature? 9:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 10:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 8:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 5:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 5:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 3:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 5:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 9:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 10:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 10:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 10:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 4:47 p.m. Aug. 16, 2012 - MarketWatch
Idenix plunges 30% on HCV drug setback 12:56 p.m. Aug. 16, 2012 - Val Brickates Kennedy
Bristol’s bad news is good for rivals: analysts 5:52 p.m. Aug. 2, 2012 - Val Brickates Kennedy
Gilead shares boosted by Bristol-Myers drug news 11:24 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Bristol-Myers falls 7% on hepatitis C drug setback 10:09 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Stocks to watch Thursday: Annie’s, Rite Aid 5:02 p.m. June 6, 2012 - David B. Wilkerson
Achillion's chief medical officer resigns 4:19 p.m. June 6, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:23 p.m. May 21, 2012 - MarketWatch

Achillion Could Win Idenix's Mystery Suitor: Analyst 11:44 a.m. June 20, 2014 - Investors Business Daily
Baird Comments On Achillion's Bullish Share Action 11:12 a.m. June 20, 2014 - benzinga.com
Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms 10:25 a.m. June 20, 2014 - Seeking Alpha
Biotech Stock Roundup: HCV Back in Focus - Idenix, Achillion Soar - Analyst Blog 10:33 a.m. June 18, 2014 - Zacks.com
Benzinga's Top #PreMarket Losers 7:12 a.m. June 18, 2014 - benzinga.com
Hepatitis C May Give A Big Boost To These Drug Stocks - If The FDA Approves 1:32 p.m. June 17, 2014 - Seeking Alpha
Achillion Set to See Shares Soar 7:44 a.m. June 17, 2014 - Barrons.com
Benzinga's Top #PreMarket Losers 7:18 a.m. June 17, 2014 - benzinga.com
Maxim's $22 Price Target On Achillion Is Far From Realistic 3:33 a.m. June 17, 2014 - Seeking Alpha
If Achillion Was Going To Be Taken Out At A Big Premium, Baupost Would Probably Own It 5:56 p.m. June 16, 2014 - Seeking Alpha
Why Achillion Pharmaceuticals (ACHN) Is Spiking Today 10:33 a.m. June 16, 2014 - TheStreet.com
Achillion Gets Massive Price Target Hike On HCV Drugs 10:27 a.m. June 16, 2014 - Investors Business Daily
Maxim Group Significantly Raises Achillion's PT, Shares Soar +15% 8:34 a.m. June 16, 2014 - benzinga.com
Mid-Afternoon Market Update: Markets Reverse Early Loses; Oil Continues To Rise On Overseas Worry 2:36 p.m. June 13, 2014 - benzinga.com
Mid-Morning Market Update: Markets Mostly Flat; Priceline To Acquire OpenTable For $103/Share 9:25 a.m. June 13, 2014 - benzinga.com
Morning Market Losers 8:44 a.m. June 13, 2014 - benzinga.com
Benzinga's Top #PreMarket Losers 7:12 a.m. June 13, 2014 - benzinga.com
Biotech ETFs – Keep Those Buyouts Coming! 9:14 a.m. June 12, 2014 - InvestorPlace.com
Achillion Pharmaceuticals (ACHN) in Focus: Stock Falls 6.4% - Tale of the Tape 8:36 a.m. June 12, 2014 - Zacks.com
Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More 7:58 a.m. June 12, 2014 - 247WallSt.com

Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. June 17, 2014 - PR Newswire - PRF
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc. 7:00 a.m. June 13, 2014 - PR Newswire - PRF
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Achillion to Present at Two Upcoming Investor Conferences 6:06 a.m. June 11, 2014 - GlobeNewswire
Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV 6:06 a.m. June 10, 2014 - GlobeNewswire
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma 8:10 a.m. June 6, 2014 - PR Newswire - PRF
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma 1:30 p.m. May 9, 2014 - PR Newswire - PRF
Achillion Reports First Quarter 2014 Financial Results 6:06 a.m. May 7, 2014 - GlobeNewswire
Achillion to Present at Three Upcoming Investor Conferences 6:31 a.m. May 1, 2014 - GlobeNewswire
Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV 4:07 p.m. April 30, 2014 - GlobeNewswire
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys 8:16 a.m. April 14, 2014 - PR Newswire - PRF
Morning Analysis on Top Gainers -- Research on Achillion Pharma, Microvision, Miller Energy Resources, and Bon-Ton Stores 11:24 a.m. March 25, 2014 - PR Newswire - PRF
Achillion Announces Oral Presentations Given at APASL 2014 Detailing Clinical Activity of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV 6:05 a.m. March 14, 2014 - GlobeNewswire
Achillion Reports 2013 Fourth Quarter and Year-End Financial Results 7:05 a.m. March 7, 2014 - GlobeNewswire
Achillion to Present at Two Upcoming Investor Conferences 7:00 a.m. Feb. 10, 2014 - GlobeNewswire
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos 9:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones 7:25 a.m. Jan. 13, 2014 - GlobeNewswire
ACHILLION PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Achillion Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ACHN 12:53 p.m. Dec. 6, 2013 - PR Newswire
Increased Quarterly Dividends, HIV Elimination Efforts, Advanced Treatment Options, and Conference Participations - Research Report on Merck, Varian, Mylan, Achillion, and Abiomed 9:00 a.m. Dec. 4, 2013 - PR Newswire
ACHN, CTIC, DRYS and FREE added to NASDAQ Active Stock Watch List at GSR 11:01 a.m. Dec. 2, 2013 - ACCESSWIRE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sustainability Investments: $17 Trillion Wager Faces Divergence

Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...

Melissa Rivers Brings Her Wit Back to Emmys Carpet

They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...

Streamlined AI Video Analytics for Public Safety Unveiled

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Fermi's Founder Pushes for Board Overhaul: What's Next?

Fermi's Roller Coaster: A Founder’s Stand Seems like Fermi Inc. is on a wild ride through the business landscape, and it's giving shareholders more whiplash than satisfaction these days. Toby Neugebauer, co-founder of Fermi and the loudest voice in the room, is feeling like his company is facing some serious turbulence and seems determined not to sit idly by as it hits...

Supply Maverick Simplifies Global Shipping Processes

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

High-Grade Copper Spurs Optimism for PolarX in Alaska

Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...

Oil Markets Shift Focus: Pipelines Trump Drilling

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

2026 Buy-Side Index Reveals State Market Variance

Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...